Facebook
Twitter
Telegram
Report an ErrorBlueprint Medicines Corporation Balance Sheet 2011-2024 | BPMC
Annual Balance Sheet Blueprint Medicines Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
22.4 M | -16.3 M | -98.5 M | - | -18 M | -53.4 M | -382 M | -48 M | -155 M | -38.2 M | 876 K | - | - |
Long Term Debt |
81.8 M | 92.8 M | 103 M | - | - | - | - | 1.52 M | 4.07 M | 7.34 M | 2.16 M | - | - |
Long Term Debt Current |
11.9 M | 10.6 M | 8.09 M | 7.94 M | 6.82 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 137 M | 60.8 M | 48.9 M | 41.2 M | 16.3 M | 7.73 M | 2.48 M | - | - |
Total Current Liabilities |
215 M | 183 M | 150 M | 131 M | 106 M | 60.3 M | 42.9 M | 28.5 M | 18.6 M | - | - | - | - |
Total Liabilities |
919 M | 835 M | 281 M | 248 M | 243 M | 121 M | 91.8 M | 69.7 M | 34.9 M | 14.5 M | 5.63 M | - | - |
Deferred Revenue |
812 K | 4.67 M | 11.5 M | 12.6 M | 6.16 M | 3.6 M | 5.37 M | 11.4 M | 5.9 M | - | - | - | - |
Retained Earnings |
-2.34 B | -1.83 B | -1.28 B | -631 M | -945 M | -598 M | -356 M | -207 M | -135 M | -82.2 M | -41.9 M | - | - |
Total Assets |
1.05 B | 1.35 B | 1.25 B | 1.72 B | 708 M | 540 M | 716 M | 283 M | 179 M | 49.9 M | 4.14 M | - | - |
Cash and Cash Equivalents |
71.3 M | 120 M | 210 M | 685 M | 114 M | 68.1 M | 400 M | 52.1 M | 163 M | 47.2 M | 1.99 M | - | - |
Book Value |
131 M | 515 M | 971 M | 1.47 B | 464 M | 419 M | 624 M | 213 M | 144 M | 35.4 M | -1.5 M | - | - |
Total Shareholders Equity |
131 M | 515 M | 971 M | 1.47 B | 464 M | 419 M | 624 M | 213 M | 144 M | -79.4 M | -41.5 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Blueprint Medicines Corporation
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
78.5 M | 81.8 M | 84 M | 87 M | 89.9 M | 92.8 M | 95.5 M | - | 101 M | 103 M | 75.1 M | 77.3 M | 79.5 M | 81.7 M | 81.7 M | 81.7 M | 81.7 M | 89.1 M | 89.1 M | 89.1 M | 89.1 M | - | - | - | - | 1.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
728 M | 919 M | 903 M | 795 M | 806 M | 835 M | 818 M | - | 262 M | 281 M | 230 M | 240 M | 225 M | 248 M | 248 M | 248 M | 248 M | 243 M | 243 M | 243 M | 243 M | 121 M | 121 M | 121 M | 121 M | 91.8 M | 91.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
7.25 M | 812 K | 3.01 M | 3.33 M | 3.74 M | 4.67 M | 4.63 M | - | 9.6 M | 11.5 M | 6.79 M | 7.91 M | 14.9 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 5.37 M | 6.07 M | 9.3 M | 10.4 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.25 B | -2.34 B | -2.23 B | -2.1 B | -1.96 B | -1.83 B | -1.67 B | - | -1.38 B | -1.28 B | -957 M | -840 M | -731 M | -631 M | -631 M | -631 M | -631 M | -945 M | -945 M | -945 M | -945 M | -598 M | -598 M | -598 M | -598 M | -356 M | -356 M | -356 M | -356 M | -207 M | -207 M | -207 M | -207 M | -135 M | -135 M | -135 M | -135 M | -82.2 M | -82.2 M | -82.2 M | -82.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.04 B | 1.05 B | 1.11 B | 1.11 B | 1.22 B | 1.35 B | 1.46 B | - | 1.14 B | 1.25 B | 1.48 B | 1.57 B | 1.63 B | 1.72 B | 1.72 B | 1.72 B | 1.72 B | 708 M | 708 M | 708 M | 708 M | 540 M | 540 M | 540 M | 540 M | 716 M | 716 M | 716 M | 716 M | 283 M | 283 M | 283 M | 283 M | 179 M | 179 M | 179 M | 179 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
113 M | 71.3 M | 56 M | 75.5 M | 170 M | 120 M | 291 M | 173 M | 37.2 M | 210 M | 554 M | 534 M | 698 M | 685 M | 685 M | 685 M | 685 M | 114 M | 114 M | 114 M | 114 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 400 M | 400 M | 400 M | 400 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M | 163 M | 163 M | 163 M | 163 M | 47.2 M | 47.2 M | 47.2 M | 47.2 M | 1.99 M | - | - | - | 3.28 M | - | - | - | - | - | - | - |
Book Value |
311 M | 131 M | 203 M | 311 M | 414 M | 515 M | 640 M | - | 882 M | 971 M | 1.25 B | 1.33 B | 1.4 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 464 M | 464 M | 464 M | 464 M | 419 M | 419 M | 419 M | 419 M | 624 M | 624 M | 716 M | 716 M | 283 M | 283 M | 283 M | 283 M | 179 M | 179 M | 179 M | 179 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
311 M | 131 M | 203 M | 311 M | 414 M | 515 M | 640 M | 748 M | 882 M | 971 M | 1.25 B | 1.33 B | 1.4 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 464 M | 464 M | 464 M | 464 M | 419 M | 419 M | 419 M | 419 M | 624 M | 624 M | 624 M | 624 M | 213 M | 213 M | 213 M | 213 M | 144 M | 144 M | 144 M | 144 M | -79.4 M | -79.4 M | -79.4 M | -79.4 M | -41.5 M | - | - | - | -20.9 M | - | - | - | - | - | - | - |
All numbers in USD currency